Galmed Pharmaceuticals (NASDAQ:GLMD) will announce its earnings results before the market opens on Wednesday, May 9th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. Galmed Pharmaceuticals had a negative net margin of 1,133.55% and a negative return on equity of 133.50%. On average, analysts expect Galmed Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ:GLMD opened at $5.93 on Monday. The firm has a market capitalization of $91.53, a price-to-earnings ratio of -6.05 and a beta of 2.72. Galmed Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $12.22.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.